Last deal
Amount
Stage
Date
all rounds
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Advancell Advanced In Vitro Cell Technologies
Advanced In Vitro Cell Technologies is a biotech nanomedicine company developing drugs and providing services and reagents.
Sector
Subsector
Keywords
Location
total rounds
total raised
Molecular Express
Molecular Express is a research and development technology company.
Sector
Subsector
Keywords
Location
Xtal BioStructures
Xtal BioStructures is a contract research organization specializing in X-ray crystallography and protein analysis.
Sector
Subsector
Location
ITSI-Biosciences
ITSI-Biosciences LLC provides bioanalytical and mass spectrometry services for various fields.
Sector
Subsector
Location
Financials
Funding Rounds1
Number of Funding Rounds
Their latest funding was raised on 12.06.2023. Their latest investor Ampersand Capital Partners. Their latest round Private Equity
Ampersand Capital Partners
Ampersand is a private equity firm focused on investments in Healthcare and Industrial sectors.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors1
Number of lead investors
Number of investors
Ampersand Capital Partners
Ampersand is a private equity firm focused on investments in Healthcare and Industrial sectors.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
David J. Parker
Dave, who has more than 15 years of private equity experience, joined Ampersand in 1994. Dave’s board seats have included Bako, NOVEX, Signature Genomics and Roadrunner. Prior to joining Ampersand, Dave spent five years consulting at Bain and Mercer and four years in corporate lending at Bank of Boston. He holds a B.A. in Government and Economics from Dartmouth and an M.B.A. from Wharton.
current job
People
Employee Profiles8
Bridget Carragher
Founder and Co-Chief Technology Officer